Looking to prepare for the next flu pandemic, Sanofi drops $700M+ into new Toronto facility for Fluzone production

With Covid-19 variants potentially sticking around in the human population for years to come and clogging up hospitals, public health officials are spotlighting the need for effective flu vaccination campaigns into the future. French drugmaker Sanofi, the maker of the world’s bestselling flu vaccine FluZone, is now dropping a major investment into its supply chain.